Anisodamine, an anticholinergic drug, has antishock effect, which is intimately linked to alpha7nAChR-dependent anti-inflammatory pathway. Anisodamine demonstrates a direct cardiac depressive action at the myocyte level, which may be related to, at least in part, NO production and cholinoceptor antagonism, it causes the changes of structure and function in the transmembrane domain of the Ca(2+)-ATPase from sarcoplasmic reticulum. Anisodamine, a vasoactive drug, can abate endogenous endotoxaemia subsequent to splanchnic vasoconstriction due to hypovolaemia, it alleviates inflammatory damage by significantly reducing the expressions of VEGF and ICAM-1, and shows significant protective effects in an animal model of infusion phlebitis. Anisodamine also inhibits shiga toxin type 2-mediated tumor necrosis factor-alpha production in vitro and in vivo. Scopolamine is a non subtype selective muscarinic and nicotinic acetylcholine receptor antagonist. Scopolamine is used in traditional Chinese medicine research for various diseases, mainly for improving microcirculation in shock state, and can also be used for organophosphate poisoning.

Butylscopolamine bromide is an organic bromide salt of butylscopolamine. It is an antispasmodic drug which can relieve painful stomach cramps (including those linked with irritable bowel syndrome), bladder and menstrual cramps. It has a role as a muscarinic antagonist and an antispasmodic drug. It is a quaternary ammonium salt and an organic bromide salt. It contains a butylscopolamine. Scopolamine butylbromide is a competitive antagonist of muscarinic acetylcholine receptor (mAChR) with an IC50 of 55.3 ± 4.3 nM, it possesses anticholinergic, and anti-tumor effects, it used as an abdominal-specific antispasmodic agent. Scopolamine butylbromide is effective in preventing succinylcholine-induced bradycardia in infants and children.